Bolstering Bowel And Bladder Control With Dignify Therapeutics’ Karl Thor

RESEARCH TRIANGLE PARK, NC (August 5, 2024) – Dignify Therapeutics (Dignify), a leading developer of therapies for bladder and bowel dysfunction, announced that Dr. Rabchevsky has joined Dignify’s Scientific Advisory Board (SAB). Dr. Rabchevsky is currently Professor of Physiology and inaugural faculty member of the Spinal Cord & Brain Injury Research Center at the University…

Dignify Therapeutics’ Chief Scientific Officer, Karl B. Thor, PhD, has been invited to participate as a Faculty member at the 2nd International Congress on Underactive Bladder – CURE-UAB in Denver, CO, Dec. 3-4, 2015.  His presentation is entitled “Pharmaceutical Targets for Drug-induced Voiding”.  This NIH-sponsored congress brings together academic, pharmaceutical, and medical device experts to…

Company RESEARCH TRIANGLE PARK, NC (October 22, 2024) – Dignify Therapeutics (Dignify), a leading developer of therapies for bladder and bowel dysfunction, has been selected as a participating company in the Praxis Spinal Cord Injury (SCI) Accelerate Program. SCI Accelerate is a commercialization program ‘geared towards healthcare companies with a product ready to launch into…

Research Triangle Park, NC – February 14, 2025 – Dignify Therapeutics, a biotechnology company dedicated to restoring voluntary bowel and bladder function in patients with neurological conditions, presented its clinical development plans for its lead assets, DTI-117 and DTI-301, at the BIO CEO & Investor Conference held in New York on February 10-11, 2025. During…